| Sheila J Brooks, DPM | |
|
324 North St Ste 1, Bluefield, WV 24701-4038 | |
| (304) 325-7079 | |
| (304) 327-0614 |
| Full Name | Sheila J Brooks |
|---|---|
| Gender | Female |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 324 North St Ste 1, Bluefield, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467442871 | NPI | - | NPPES |
| 3810011431 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 230 (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sheila J Brooks, DPM Po Box 690, Bluefield, WV 24701-0690 Ph: (304) 325-7079 | Sheila J Brooks, DPM 324 North St Ste 1, Bluefield, WV 24701-4038 Ph: (304) 325-7079 |
News Archive
Sigma-Aldrich Corporation today announced that its custom manufacturing and services business unit, SAFC, will consolidate its global chiral chromatography screening and small scale purification operations and locate them at its Pharmorphix Solid State Research Laboratories in Cambridge, UK, to support its new integrated chiral chemistry offer.
The Senate Finance Committee's so-called "gang of six" will hold a conference call Friday to continue negotiations on a possible bipartisan health care compromise, as a Sept. 15 deadline set by Democrats approaches. "But the prospects of reaching such an agreement within 11 days have fallen as politics has crept further into the debate," the Washington Times reports.
Two to three in every 1,000 children are born with a hearing loss that is likely to impact development. Research of the auditory system at its early developmental stages, and efforts to identify hearing loss and initiate appropriate rehabilitation strategies, can be crucial to the healthy development of a child.
A new review suggests public health measures such as mask-wearing, universal lockdowns, and temporary shutdowns of businesses and schools helped prevent further SARS-CoV-2 transmission.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 9 days ago
Dr Brooks Foot Care Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 324 North St Ste 1, Bluefield, WV 24701 Phone: 304-325-7079 Fax: 304-327-0614 |